Supriya Lifescience Reports Q2 FY27 Results and Expansion Updates
Supriya Lifescience Ltd 路 Investor Presentation 路 06 Nov 2026, 6:53 pm
Supriya Lifescience Reports Q2 FY27 Results and Expansion Updates Supriya Lifescience reported Q2 FY27 revenue of INR 2,063.0 Mn, up 3.2% YoY (8.7% QoQ), while EBITDA dropped 37.5% YoY to INR 454.0 Mn, with margins contracting 1,435 bps YoY to 22.0%. PAT fell 42.0% YoY to INR 292.5 Mn (14.2% margin). For H1 FY27, revenue reached INR 3,960.4 Mn (up 14.8% YoY), and PAT stood at INR 532.9 Mn. The company launched two inhalation anesthetics from Ambernath, is developing GLP-1 products, patented a novel Semaglutide formulation, and plans six EU dossier filings in FY27.
Original exchange filing (PDF)
More announcements from Supriya Lifescience Ltd
- Earnings Call Transcript is enclosed herewith. 路 13 Nov 2026
- Outcome of the Results Earning Call for Quarter and Half year ended September 30, 2026 is enclosed herewith. 路 07 Nov 2026
- Press Release is enclosed herewith. 路 07 Nov 2026
- Change In Management - Appointment of Senior Management Personnel of the Company. 路 06 Nov 2026
- Please find enclosed. 路 06 Nov 2026
- Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 06 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held .... 路 06 Nov 2026
- Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record. 路 03 Nov 2026
